ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1875

A Patient and Physician Survey of Impact and Management of Fibromyalgia Across Latin America and Europe

Patricia Clark, Unidad de Epidemilogia Clinica, Hospital Infantil de México Federico Gómez, Mexico City, Mexico

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Diagnostic criteria, Fatigue, fibromyalgia, pain and quality of life

  • Tweet
  • Email
  • Print
Session Information

Title: Fibromyalgia and Soft Tissue Disorders

Session Type: Abstract Submissions (ACR)

Background/Purpose: Differences in healthcare practices around the world have been reported; however any impact on management of chronic conditions is often unclear. We surveyed patients and physicians from three Latin American (LA) and six European countries to ascertain differences in journey to diagnosis and management of fibromyalgia (FM).

Methods: Data from 900 FM patients (300 LA; 600 Europe) and 1824 GPs/specialists (604 LA; 1220 Europe) were collected between 2008 and 2010.Patients and physicians completed separate questionnaires, which included questions on symptoms (14 common symptoms), management, and impact of FM. Patient interviews (face-to-face or via telephone; ~25mins) were conducted in local languages (Spanish, Portuguese). Rating scales were used throughout. Data were analyzed using cross tabulations and descriptive statistics; no multivariate analysis. Significance determined at P<0.05 (indicated by *)

Results: Patients from LA reported FM symptoms for longer time (100.8 vs 83.7* months), took longer to be diagnosed (42.3 vs 31.1* months), and saw more physicians to receive a diagnosis (5.4 vs 4.0*) vs European patients, respectively. FM was characterized by multiple symptoms in both regions, although a higher proportion of patients from LA vs Europe reported common FM symptoms, including widespread pain (92% vs 62%*), sleep problems (84% vs 49%*), and fatigue (88% vs 46%*). Patients from LA rated their pain higher on a 10-point scale vs European patients (8.0 vs 7.2*). Patients from both regions reported common FM symptoms as disruptive to their quality of life (pain: 86% vs 78%*; sleeping problems: 80% vs 76%; fatigue: 80% vs 75%). Patients from LA more often reported that FM had impacted their ability to work and/or earn an income vs patients from Europe. LA patients were managed by different healthcare professionals, while European patients were mostly treated by GPs (47% vs 96%*). Physicians principally considered widespread pain as a typical FM symptom and being disruptive to patient’s. Although >50% of patients considered them common symptoms, <10% of GPs or specialists from either region considered problems sleeping or fatigue typical FM symptoms. Physicians from LA more often considered problems sleeping*, difficulty concentrating*, anxiety*, depression*, numbness/tingling*, and leg cramps* disruptive vs European physicians.

Conclusion: Differences between FM characteristics, treatment practices, and opinions were noted by physicians and patients from LA and Europe. Improved understanding of these complexities involved in FM in different healthcare settings may help target educational/training programs towards improving aspects of chronic care. Improving alignment between perception of FM from the patient and physician’s perspective may also improve patient management.


Disclosure:

P. Clark,

Pfizer Inc,

5;

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-patient-and-physician-survey-of-impact-and-management-of-fibromyalgia-across-latin-america-and-europe/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology